SAN DIEGO and NEW JERSEY, Oct. 29,
2018 /PRNewswire/ -- OncoSec Medical Incorporated
(OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer
immunotherapies, today announced the appointment of Kellie Malloy Foerter to the position of Chief
Clinical Development Officer.
As Chief Clinical Development Officer, Ms. Malloy Foerter will be responsible for leading
OncoSec's ongoing registration-enabled KEYNOTE-695, a global,
multicenter Phase 2b, open-label
trial of intratumoral delivery of TAVOTM (tavokinogene
telseplasmid / plasmid IL-12) with intravenous KEYTRUDA®
(pembrolizumab) in patients with refractory, unresectable Stage III
or Stage IV metastatic melanoma who have failed prior anti-PD-1
treatment with KEYTRUDA or OPDIVO® (nivolumab). In
addition to working to rapidly advance OncoSec's growing clinical
pipeline, she will also be responsible for leading OncoSec's second
ongoing TAVOTM / KEYTRUDA® combination
clinical trial in triple negative breast cancer (TNBC),
KEYNOTE-890.
"I am delighted to welcome Kellie to the OncoSec team, as I know
firsthand the rigor and creativity she brings with respect to
clinical trial design, execution and analysis. I have no doubt she
will an invaluable resource to the company as we continue to
advance our clinical development pipeline, including both
KEYNOTE-695 and KEYNOTE-890," said Daniel J. O'Connor, President and Chief
Executive Officer of OncoSec.
With nearly three decades of experience in clinical research,
Ms. Malloy Foerter joins OncoSec
from Syneos Health, where she served as Executive Vice President
and General Manager, Clinical Solutions. As a member of the Syneos
Health Clinical executive leadership team, Ms. Malloy Foerter was responsible for the
development and growth of multiple portfolios across therapeutic
areas which included a strong focus on oncology and hematology
trials, for the world's leading biopharmaceutical companies.
Earlier, Ms. Malloy Foerter
spent 20 years at inVentiv Health (previously PharmaNet) where she
held multiple positions of increasing responsibility, most recently
serving as Senior Vice President, Clinical Research. Prior to
inVentiv, she served as Senior Project Associate, Clinical Research
Associate and Clinical Studies Assistant at Covance.
In connection with her appointment, Ms. Malloy Foerter received a one-time inducement
award of 200,000 stock options and 50,000 restricted stock units
(RSUs), of which 50,000 options (25%) and 12,500 RSUs (25%) are
fully vested as of the grant date. The remaining options and
RSUs vest over a three-year period. The Company approved the
award as an inducement material to Ms. Malloy Foerter entering into employment with the
Company in accordance with NASDAQ Listing Rule 5635(c)(4).
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. OPDIVO® is a
registered trademark Bristol-Meyers Squibb.
About OncoSec Immunotherapies
OncoSec is a
clinical-stage biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's
immune system to target and attack cancer. OncoSec's lead
immunotherapy platform – TAVOTM (tavokinogene
telseplasmid) – enables the intratumoral delivery of DNA-based
interleukin-12 (IL-12), a naturally occurring protein with
immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the body.
OncoSec has built a deep and diverse clinical pipeline utilizing
TAVOTM as a potential treatment for multiple cancer
indications either as a monotherapy or in combination with leading
checkpoint inhibitors; with the latter potentially enabling OncoSec
to address a great unmet medical need in oncology: anti-PD-1
non-responders. Results from recently completed clinical
studies of TAVOTM have demonstrated a local immune
response, and subsequently, a systemic effect as either a
monotherapy or combination treatment approach. In addition to
TAVOTM, OncoSec is identifying and developing new
DNA-encoded therapeutic candidates and tumor indications for use
with its ImmunoPulse® platform. For more information,
please visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
dschemelia@tiberend.com
jrando@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-appoints-kellie-malloy-foerter-as-chief-clinical-development-officer-300739293.html
SOURCE OncoSec Medical Incorporated